Cellular Biomedicine Group (CBMG) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
Cellular Biomedicine Group Reports Second Quarter and First Half 2015 Financial Results and Business Highlights
August 14, 2015 7:00 AM EDTSHANGHAI, China and PALO ALTO, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, 2015.
"I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our international-standard... More
Cellular Biomedicine Group Reports Second Quarter and First Half 2015 Financial Results and Business Highlights
August 14, 2015 7:00 AM EDTSHANGHAI, China and PALO ALTO, Calif., Aug. 14, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results and business highlights for the quarter and six months ended June 30, 2015.
"I am pleased with our second quarter progress in reaching certain planned milestones and in strengthening both our business and technological advantages," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "In addition to our international-standard... More
